ZLDPF — Zealand Pharma A/S/ADR

OTC · Unknown · Unknown · CIK 2068427 · Denmark
Last close
$45.01
Market Cap
$3.14B
52W High
$55.36
52W Low
$38.50
ADV30
1,203
Next earnings
2026-05-07
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 34,000,000 34,000,000 -539,000,000 -394,000,000 15,301,000,000 3,849,000,000 832,000,000
Dec 2025 68,915,000 68,915,000 -356,544,000 -379,115,000 15,948,798,000 4,576,541,000 1,118,185,000
Sep 2025 49,569,000 49,569,000 -461,320,000 -404,233,000 16,797,246,000 5,972,711,000 1,634,645,000
Jun 2025 9,088,284,000 9,087,874,000 8,338,423,000 7,573,697,000 17,180,064,000 7,244,047,000 1,571,270,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$6,531,933,000
Investing CF
$-2,248,506,000
Financing CF
$-378,182,000
CapEx
$-69,073,000
Dividends Paid
Buybacks
$-345,566,000
EPS Diluted TTM
$91.34
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$6,287,000
Inventory
$0
Receivables
ST Investments
$10,532,267,000
EBIT TTM
$7,030,122,000
Pretax Income TTM
$7,001,063,000
Interest Exp TTM
$29,059,000
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$9,240,859,648
EBITDA
$6,799,047,168
Free Cash Flow
$4,224,191,744
Enterprise Value
$-10,873,589,760
Total Cash
$14,467,999,744
Total Debt
$414,000,000
Shares Out
69,699,276
Trailing EPS
$13.94
Book Value
$32.52
ROE
56.2%
ROA
34.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 9,214,860,000 7,113,523,000 6,455,008,000 15,948,798,000 1,118,185,000 6,531,933,000
Dec 2024 62,691,000 -1,269,071,000 -1,078,828,000 9,505,600,000 888,858,000 -930,816,000
Dec 2023 342,788,000 -577,217,000 -703,739,000 1,979,993,000 387,154,000 -425,668,000
Dec 2022 103,986,000 -816,599,000 -1,202,135,000 1,539,806,000 723,895,000 -942,311,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.16

Peers — same industry

TickerNameMarket CapLastDaily %
RCWLY Rockwool A/S/ADR $3.12B $32.00
FLNC Fluence Energy, Inc. $3.11B $23.42
PUGBY Puig Brands S.A./ADR $3.18B $9.35
CALY Callaway Golf Co $3.09B $17.20
COHU COHU INC $3.09B $65.45

News headlines (Yahoo Finance, 1h cache)

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Grow
2026-06-16 22:30 · Yahoo
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
2026-06-15 15:00 · Yahoo
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
2026-06-10 20:00 · Yahoo
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
2026-06-08 16:34 · Yahoo
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
2026-06-08 15:05 · Yahoo
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
2026-06-08 15:00 · Yahoo
Why The Narrative Around Zealand Pharma (CPSE:ZEAL) Is Shifting After Target Resets And Trial Updates
2026-06-08 06:11 · Yahoo
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in p
2026-06-07 18:30 · Yahoo
New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people li
2026-06-05 20:45 · Yahoo
Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference
2026-06-02 15:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.